Analysis of the latest price and purchasing channels of Osimertinib

Osimertinib is a third-generation EGFR-TKI targeted drug that is widely used to treat patients with non-small cell lung cancer carrying EGFR T790M mutations or sensitive mutations. The drug is highly selective and well tolerated, and can effectively delay disease progression and improve survival. At present, osimertinib has been officially launched in mainland China and has been included in the national medical insurance directory, which has greatly reduced the financial burden on patients. The mainstream specifications sold in China are 80 mg*30 tablets, and the latest price is about five to six thousand yuan. The actual out-of-pocket amount after medical insurance varies depending on the region and reimbursement policy, and can generally drop to less than a few thousand yuan.

For patients who are not eligible for medical insurance or want to seek low-cost alternatives, some people will focus on the overseas generic drug market. Laos and Bangladesh have approved the official marketing of generic drugs of osimertinib. Its drug ingredients, dosage and therapeutic effects are basically the same as those of the original drug. Overseas generic drugs’ 80 mg*30 tablets are priced at around a few hundred yuan, which is more economically advantageous than original drugs. It should be noted that these drugs must be obtained through formal channels, such as nationally certified international pharmacies or officially authorized drug import platforms. Do not purchase through informal channels or personal channels to prevent the purchase of counterfeit drugs or inferior products.

In terms of purchasing channels, if domestic patients are diagnosed by a doctor and have indications for medication, they can purchase the original version of osimertinib at pharmacies of tertiary hospitals, designated pharmacies for medical insurance or official online pharmacies with a prescription. If overseas channels are considered, it should be verified whether the drug manufacturer has legal drug production approval documents and export licenses, and whether the drug transportation and storage meet standard conditions. Compliance channels not only ensure drug quality, but also ensure the safety of subsequent medical supervision and medication tracking.

Overall, the accessibility of osimertinib in China has been greatly improved, and the cost-effectiveness has been significantly improved after medical insurance coverage, which can meet the clinical needs of most patients. Although overseas generic drugs are low in price, there are certain regulatory differences and legal risks. Patients should give priority to purchasing drugs through formal domestic channels under the guidance of their attending doctors; if they really need overseas versions, they must purchase them through compliant and regulated platforms to ensure efficacy, safety and legality.

Reference materials:https://www.drugs.com/